The major cause of mortality in breast cancer is the progression of metastatic disease. Although loss of oestrogen receptors (ER) and progesterone receptors is associated with more aggressive disease, 30% of patients with receptor-positive, node-negative tumours develop metastases (Price et al, 1997). A component of the metastatic process is invasion, which is accomplished when the cells can transit the extracellular matrix (ECM) layer. More accurate prognoses might be possible if factors could be identified that either promote invasion or are markers for it, independent of steroid receptor status. Specific treatments to prevent invasion might also be developed.
leaving cells that had migrated on the underside of the membrane. Membranes were stained with Diff Quik, dried and analysed with the NIH Image program. About 20% of the total membrane area was counted. Each experimental point had four replicates.
Flow cytometry
Cells were harvested for flow cytometry by scraping into BSA medium plus protease inhibitors (aprotinin 1.6 U ml Ð1 , soybean trypsin inhibitor 2 µg ml Ð1 , leupeptin 2 µg ml Ð1 , pepstatin 7 µg ml Ð1 , antipain 37 µg ml Ð1 , bestatin 0.1 µg ml Ð1 ). Cells were washed once with the same medium, counted, washed with phosphate buffered salineÐ0.1% azide (PBSA), and diluted for assay in PBSA. Aliquots of 10 6 cells were incubated with primary antibody, washed twice with PBSA, incubated with FITC-labelled goat anti-mouse (IgG and IgM) (BoehringerÐMannhein), washed twice and analysed in a FACScan instrument (BectonÐDickinson).
The primary antibody, PF-11, is a monoclonal raised against a peptide containing residues 29Ð69 of the human TR-1 (Kranzhofer et al, 1996) , which includes the thrombin binding site and the anion-binding exosite of TR-1. It was generously provided by Dr Shaun Coughlin, UCSF. A mouse IgG, 2b (Sigma), was the isotype control.
Stable transfection with pHEO
MDA-MB231 cells were stably transfected with pHEO to form the oestrogen receptor-positive cell line MDAL3, as previously described (Tora et al, 1989; Pentecost, 1998) .
Statistics
Results are presented as means ± s.e.m. Data were analysed by StudentÕs two tailed test or by ANOVA with the StudentÐ NewmanÐKeuls post test for differences among groups.
RESULTS

Thrombin-stimulated invasion through Matrigel
The three cell lines have been characterized in the literature as highly invasive (MDA-MB231), moderately invasive (MDA-MB436), and minimally invasive (MCF-7) (Thompson et al, 1992) . The relative invasiveness of the cell lines was confirmed as shown in Figure 1 . The extent of thrombin-stimulated invasion is given relative to control values. The broad differences in the number of migratory cells in control samples, 51 for MCF-7 cells, 217 for MDA-MB436 cells, and 317 for MDA-MB231 cells, emphasize the very different inherent invasive capacities of these cell lines on a Matrigel matrix. The effect of 100 nM thrombin on invasion is also given. Thrombin stimulated invasion in the MDA-MB231 cell line, but did not stimulate MDA-MB436 or MCF-7 cells.
Thrombin is a stimulator of movement, not a chemoattractant, in invasion assays. The chemoattractant is the 3T3-conditioned medium in the well, whereas the thrombin is placed in the insert with the cells. The concentration dependence of thrombin stimulation is shown in Figure 2 . Data are reported relative to invasion by the unstimulated cell cultures. MDA-MB231 cells were stimulated by all concentrations above 0.1 nM. MDA-MB436 cells and MCF-7 cells were not stimulated by any concentration of thrombin, up to 100 nM. Thrombin had no effect on the viability of the cell lines (data not shown).
Actions of thrombin can be inhibited by hirudin, a highly specific inhibitor of proteolysis by thrombin. Effects that occur through the thrombin receptor, TR-1, require enzymatically active thrombin and can be elicited by thrombin receptor activating peptide (TRAP). Thrombin-stimulated invasion by MDA-MB231 cells, shown in Figure 3 , was completely eliminated by a slight molar excess of hirudin (140 nM hirudin and 100 nM thrombin), whereas hirudin alone had no effect. Similar results (not shown) were obtained with thrombin inactivated with the highly specific thrombin inhibitor, ProÐPheÐArg chloromethyl ketone (PPACK). Stimulation of invasion by 50 µM TRAP, also shown in Figure 3 , demonstrated the role of TR-1 in thrombin action. No stimulation occurred with an unrelated peptide, TCHDVLNETLLHG, not shown.
Effect of thrombin on chemotaxis
Movement of cells through the uncoated membrane of an invasion chamber (chemotaxis) is a measure of cell motility, independent of attachment to or digestion of ECM. Figure 4 shows that 100 nM thrombin had no effect on chemotaxis except in MCF-7 cells where it increased the number of migrating cells from 25 to 30.
The absence of a TR-1-mediated effect on chemotaxis was confirmed by experiments with TRAP. At 50 µM, TRAP had no effect on chemotaxis for any of the three cell lines, as shown in Figure 5 .
A failure of thrombin to stimulate chemotaxis would result if the thrombin diffused through the open pores of the invasion chamber and digested the chemoattractant in the well. To eliminate that possibility, 3T3-conditioned medium was pretreated with thrombin and the excess thrombin was inactivated with PPACK. The treated media were then used as the chemoattractant for invasion assays with MDA-MB231 cells. If thrombin digested the chemotaxin, the treated media would not stimulate invasion. Chemotaxis and TRAP. Two or three independent experiments were carried out with each cell line, with four replicates of control samples and four to six replicates of TRAP samples. The actual mean number of stained cells in the controls was 1068 ± 160 for MDA-MB231 cells, 138 ± 32 for MDA-MB436 cells, and 18 ± 1.8 for MCF-7 cells. There was no effect of 50 µM TRAP on chemotaxis
Media treated with thrombin and PPACK or PPACK only stimulated 50% of the invasion stimulated by control media. Addition of thrombin to the cells (50 nM) resulted in a two-to threefold stimulation of invasion. The absence of an effect of thrombin on chemotaxis cannot be attributed to destruction of the chemotaxin.
TR-1 on cell surfaces
To demonstrate TR-1 on the surface of the three cell lines, cells were harvested by scraping, labelled with monoclonal antibody PF-11 for TR-1, and analysed by flow cytometry. The results of a typical determination are shown in Figure 6 . For both MCF-7 and MDA-MB436 cells, the PF-11-labelled peak coincided with the isotype control, indicating the absence of detectable TR-1 on the surface of these cell lines. The MDA-MB231 cells had a slightly shifted peak with PF-11, indicating the presence of TR-1 on these cells. Because the differences between control and PF-11-treated cells were small, these experiments were repeated five to seven times with duplicate samples. Averaged data, shown in Table 1 , were subjected to statistical analysis, which gives validity to the detection of TR-1 on MDA-MB231 cells.
Oestrogen receptor and TR-1 expression
To investigate whether a link exists between oestrogen and TR-1, the MDAL3 cell line, derived from MDA-MB231 cells by stable transfection with the pHEO oestrogen receptor construct (Tora et al, 1989; Pentecost, 1998) , was used. Cells were grown with or without 10 nM oestradiol for 5Ð7 days until confluence was reached. TR-1 was assayed by flow cytometry. As shown in Table 2 , TR-1 was present in the MDAL3 cells; there was no difference in the amount of TR-1 detected in the cells whether oestradiol was present or not.
DISCUSSION
Thrombin has long been thought to play a role in cancer biology. Activation of coagulation in cancer patients was first observed in 1865 (Wojtukiewicz et al, 1993) ; in the 1930s, it was suggested that coagulation factors might contribute to tumour growth (Zacharski, 1996) . Anti-thrombotic therapy with warfarin or with heparin has been beneficial in the treatment of small-cell lung carcinoma (Zacharski et al, 1992; Zacharski and Costantini, 1995) .
Understanding of the cellular role of thrombin in tumour biology is incomplete. Zacharski et al (1995) have demonstrated the presence of thrombin by immunohistochemistry on cells of small-cell lung carcinoma, renal carcinoma and melanoma. Nierodzik et al (1996) demonstrated the presence of TR-1 on the surface of six (non-breast) tumour cell lines and showed that receptor activation increased platelet adhesion and tumour tyrosine phosphorylation. Wojtukiewicz et al (1993) showed that thrombin enhanced tumour cell adhesion to endothelial cells and to fibronectin, a process vital for metastasis to occur.
In vitro invasion, assayed by movement of cells through a layer of ECM, provides a good experimental system to study this component of metastasis. Although the results do not correlate precisely with metastatic potential in vivo, these assays are a good measure of tumour aggressiveness (Thompson et al, 1992; Azzam et al, 1993) .
The results reported here show clearly that thrombin potentiates invasion in a breast tumour cell line through an action of its receptor, TR-1. TR-1 is a 7-transmembrane-domain receptor, coupled to G i and to G q . Stimulation of a cell by thrombin has many effects including: stimulation of phospholipases C, A2 and D; an increase in cytosolic free Ca ++ ; activation of protein kinase C, MAP kinases and tyrosine kinases; suppression of cAMP synthesis; stimulation of mitogenesis (Brass, 1995; Brass et al, 1997) .
Thrombin is not a chemoattractant in the experiments reported here. Instead, it is a stimulator of invasion because it is added directly to the cells in the invasion chamber. Of the three cell lines, only the MDA-MB231 cells have detectable TR-1 on their surface, and only MDA-MB231 cells respond to thrombin with increased invasion. Thrombin has no effect on chemotaxis with MDA-MB231 cells, so alterations in motility (the capacity of the cells to move) can be ruled out as the mechanism of the thrombin effect. Thrombin does stimulate motility of the MCF-7 cell line, despite the absence of detectable TR-1 on these cells. MCF-7 may have a very low level of TR-1 (undetectable by flow cytometry), or it may respond to thrombin through one of the other protease-activated receptors. For the stimulation of chemotaxis to occur without stimulation of invasion indicates that MCF-7 has little or no ability to digest ECM and permit cell movement.
Expression of TR-1 in these cell lines is independent of ER. Transfection of MDA-MB231 with pHEO (to give MDAL3) did not affect expression of TR-1; the level of TR-1 in MDAL3 cells was not statistically different from that of the parental cells. Expression in MDAL3 cells was not affected by oestradiol in the growth medium. We did find that cell number in the presence of oestradiol was reduced to 70% of the value in the absence of oestradiol. Thus, we confirmed the observation from RochefortÕs laboratory (Garcia et al, 1997 ) that oestrogen slows the growth of the transfected cells. Whatever thrombinÕs involvement is in tumour invasion, it occurs through TR-1 because the thrombin effects also occur after TRAP stimulation of the cells. Thus, direct activation by thrombin of matrix metalloproteinases (MMPs) or tissue plasminogen activator is not consistent with our results.
A key question then is whether thrombin and TR-1 can be implicated in invasion through altered expression of MMPs and/or integrins.
MMPs and their role in cancer have been objects of intense research; stromelysin 3 expression (Chenard et al, 1996) and MMP-2 (gelatinase A) activation Bae et al, 1993; Thompson et al, 1994) are associated with increased invasion by breast cancer cell lines. Thrombin effects on MMPs have been studied in vascular cells; thrombin activates pre-existing MMP-2 in vascular endothelial and smooth muscle cells (Zucker et al, 1995; Galis et al, 1997) . Evidence for the induction of expression of MMPs by thrombin is not extensive: in vascular endothelial cells, MMP-3 (but not MMP-2) is induced by thrombin (Duhamel-Clerin et al, 1997) .
Integrins are cell-surface receptors for ECMs. Alteration in their expression as tumours progress has also been an intensely studied field. The integrin α2β1, which is widely expressed on breast tumour cells, is a receptor for collagen and laminin in less aggressive breast tumour cell lines, but loses its laminin receptor function in more aggressive cell lines such as MDA-MB231 (Maemura et al, 1995) . A connection has been made between TR-1 and integrin expression in human colon cancer, rat carcinosarcoma and mouse melanoma (Wojtukiewicz et al, 1995) . In these cells, thrombin or the TRAP peptide stimulated cell adhesion to fibronectin. Because integrin α3β1 is a fibronectin receptor (Gui et al, 1997) , these results suggest that increased expression of an integrin could result from activation of TR-1.
Thrombin and its receptor, TR-1, are implicated in stimulating invasive activity in MDA-MB231 breast cancer cells. TR-1 expression and thrombin activity appear to be independent of oestrogen receptor expression. TR-1 expression might serve as a prognostic indicator, independent of ER status, of aggressive, invasive breast cancer.
